Latest Gemcitabine Stories
SAN DIEGO, Dec. 19, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with Lower Performance Status Phase
BOTHELL, Wash. and VANCOUVER, British Columbia, Dec. 16, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
- ABRAXANE plus gemcitabine to be PBS listed for Australian patients with metastatic pancreatic cancer from 1 November MELBOURNE, Australia, Oct.
Lawrence Livermore biomedical researcher Mike Malfatti is working with two researchers at the University of California, Davis, Comprehensive Cancer Center to leverage dramatic advances in biological
Preclinical Data Indicates Targeting Hyaluronan in the Tumor Stroma May Offer A New Approach to Pancreatic Cancer Treatment SAN DIEGO, Oct.
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical Pathology.
CORAL SPRINGS, Florida, September 19, 2014 /PRNewswire/ -- BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of
SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S.
High unmet need addressed with first new approved treatment in eighteen years MISSISSAUGA, ON, August 6, 2014 /CNW/ - Health Canada has approved (Pr)ABRAXANE(®)
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.